Extensor truncal dystonia: Successful treatment with botulinum toxin injections
Identifieur interne : 005009 ( Main/Exploration ); précédent : 005008; suivant : 005010Extensor truncal dystonia: Successful treatment with botulinum toxin injections
Auteurs : Cynthia L. Comella [États-Unis] ; Kathleen M. Shannon [États-Unis] ; Jeana Jaglin [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 1998-05.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Adult, Back, Botulinum Toxins, Type A (administration & dosage), Botulinum toxin, Case study, Chemotherapy, Clostridium botulinum, Dystonia, Dystonia (drug therapy), Dystonia (etiology), Electromyography (drug effects), Extensor muscle, Female, Human, Humans, Injections, Intramuscular, Male, Middle Aged, Neurologic Examination (drug effects), Tardive dystonia, Torticollis (drug therapy), Torticollis (etiology), Toxin, Treatment, Treatment Outcome, Truncal dystonia, Trunk.
- MESH :
- chemical , administration & dosage : Botulinum Toxins, Type A.
- drug effects : Electromyography, Neurologic Examination.
- drug therapy : Dystonia, Torticollis.
- etiology : Dystonia, Torticollis.
- Adult, Back, Female, Humans, Injections, Intramuscular, Male, Middle Aged, Treatment Outcome.
Abstract
Patients with truncal extension dystonia, manifested by involuntary back arching, often associated with pain and severe motor disability, have not consistently responded to pharmacologic agents. We evaluated 4 women and 1 man (mean age, 41.8 years; dystonia duration, 9.8 years) with severe idiopathic (2 patients) or tardive (3 patients) truncal and cervical dystonia. Using electromyographic guidance, we injected botulinum toxin into the paravertebral muscles of the lumbar region in four to six sites using 25–50 U per site. We reevaluated patients 2–4 weeks after injection. The mean dose of botulinum toxin into back muscles was 210 U (range, 150–300 U). By blinded videotape evaluation, objective improvement was found in three patients with a mean truncal dystonia score improving by 37%. Patient evaluation showed improvement in movement ranging from 20–80% (mean, 46%) after botulinum toxin. In all patients with pain as a result of dystonia, there was substantial improvement. None of the patients worsened and no adverse effects occurred. Botulinum toxin injections offer a potent new treatment for truncal dystonia.
Url:
DOI: 10.1002/mds.870130330
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002F10
- to stream Istex, to step Curation: 002F10
- to stream Istex, to step Checkpoint: 003744
- to stream PubMed, to step Corpus: 004408
- to stream PubMed, to step Curation: 004408
- to stream PubMed, to step Checkpoint: 004440
- to stream Ncbi, to step Merge: 004F75
- to stream Ncbi, to step Curation: 004F75
- to stream Ncbi, to step Checkpoint: 004F75
- to stream Main, to step Merge: 007F21
- to stream PascalFrancis, to step Corpus: 003014
- to stream PascalFrancis, to step Curation: 003810
- to stream PascalFrancis, to step Checkpoint: 003021
- to stream Main, to step Merge: 008145
- to stream Main, to step Curation: 005009
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Extensor truncal dystonia: Successful treatment with botulinum toxin injections</title><author><name sortKey="Comella, Cynthia L" sort="Comella, Cynthia L" uniqKey="Comella C" first="Cynthia L." last="Comella">Cynthia L. Comella</name></author><author><name sortKey="Shannon, Kathleen M" sort="Shannon, Kathleen M" uniqKey="Shannon K" first="Kathleen M." last="Shannon">Kathleen M. Shannon</name></author><author><name sortKey="Jaglin, Jeana" sort="Jaglin, Jeana" uniqKey="Jaglin J" first="Jeana" last="Jaglin">Jeana Jaglin</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:FBFAB686DC5D67A5E411812E7FA90B90E7BEEB3E</idno><date when="1998" year="1998">1998</date><idno type="doi">10.1002/mds.870130330</idno><idno type="url">https://api.istex.fr/document/FBFAB686DC5D67A5E411812E7FA90B90E7BEEB3E/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002F10</idno><idno type="wicri:Area/Istex/Curation">002F10</idno><idno type="wicri:Area/Istex/Checkpoint">003744</idno><idno type="wicri:doubleKey">0885-3185:1998:Comella C:extensor:truncal:dystonia</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:9613753</idno><idno type="wicri:Area/PubMed/Corpus">004408</idno><idno type="wicri:Area/PubMed/Curation">004408</idno><idno type="wicri:Area/PubMed/Checkpoint">004440</idno><idno type="wicri:Area/Ncbi/Merge">004F75</idno><idno type="wicri:Area/Ncbi/Curation">004F75</idno><idno type="wicri:Area/Ncbi/Checkpoint">004F75</idno><idno type="wicri:doubleKey">0885-3185:1998:Comella C:extensor:truncal:dystonia</idno><idno type="wicri:Area/Main/Merge">007F21</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:98-0262037</idno><idno type="wicri:Area/PascalFrancis/Corpus">003014</idno><idno type="wicri:Area/PascalFrancis/Curation">003810</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">003021</idno><idno type="wicri:doubleKey">0885-3185:1998:Comella C:extensor:truncal:dystonia</idno><idno type="wicri:Area/Main/Merge">008145</idno><idno type="wicri:Area/Main/Curation">005009</idno><idno type="wicri:Area/Main/Exploration">005009</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Extensor truncal dystonia: Successful treatment with botulinum toxin injections</title><author><name sortKey="Comella, Cynthia L" sort="Comella, Cynthia L" uniqKey="Comella C" first="Cynthia L." last="Comella">Cynthia L. Comella</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurologic Sciences, Rush‐Presbyterian‐St. Luke's Medical Center, Chicago, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Shannon, Kathleen M" sort="Shannon, Kathleen M" uniqKey="Shannon K" first="Kathleen M." last="Shannon">Kathleen M. Shannon</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurologic Sciences, Rush‐Presbyterian‐St. Luke's Medical Center, Chicago, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author><author><name sortKey="Jaglin, Jeana" sort="Jaglin, Jeana" uniqKey="Jaglin J" first="Jeana" last="Jaglin">Jeana Jaglin</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurologic Sciences, Rush‐Presbyterian‐St. Luke's Medical Center, Chicago, Illinois</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1998-05">1998-05</date><biblScope unit="vol">13</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="552">552</biblScope><biblScope unit="page" to="555">555</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">FBFAB686DC5D67A5E411812E7FA90B90E7BEEB3E</idno><idno type="DOI">10.1002/mds.870130330</idno><idno type="ArticleID">MDS870130330</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Back</term><term>Botulinum Toxins, Type A (administration & dosage)</term><term>Botulinum toxin</term><term>Case study</term><term>Chemotherapy</term><term>Clostridium botulinum</term><term>Dystonia</term><term>Dystonia (drug therapy)</term><term>Dystonia (etiology)</term><term>Electromyography (drug effects)</term><term>Extensor muscle</term><term>Female</term><term>Human</term><term>Humans</term><term>Injections, Intramuscular</term><term>Male</term><term>Middle Aged</term><term>Neurologic Examination (drug effects)</term><term>Tardive dystonia</term><term>Torticollis (drug therapy)</term><term>Torticollis (etiology)</term><term>Toxin</term><term>Treatment</term><term>Treatment Outcome</term><term>Truncal dystonia</term><term>Trunk</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Botulinum Toxins, Type A</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Electromyography</term><term>Neurologic Examination</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dystonia</term><term>Torticollis</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dystonia</term><term>Torticollis</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Back</term><term>Female</term><term>Humans</term><term>Injections, Intramuscular</term><term>Male</term><term>Middle Aged</term><term>Treatment Outcome</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Chimiothérapie</term><term>Clostridium botulinum</term><term>Dystonie</term><term>Etude cas</term><term>Homme</term><term>Muscle extenseur</term><term>Toxine</term><term>Traitement</term><term>Tronc</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Patients with truncal extension dystonia, manifested by involuntary back arching, often associated with pain and severe motor disability, have not consistently responded to pharmacologic agents. We evaluated 4 women and 1 man (mean age, 41.8 years; dystonia duration, 9.8 years) with severe idiopathic (2 patients) or tardive (3 patients) truncal and cervical dystonia. Using electromyographic guidance, we injected botulinum toxin into the paravertebral muscles of the lumbar region in four to six sites using 25–50 U per site. We reevaluated patients 2–4 weeks after injection. The mean dose of botulinum toxin into back muscles was 210 U (range, 150–300 U). By blinded videotape evaluation, objective improvement was found in three patients with a mean truncal dystonia score improving by 37%. Patient evaluation showed improvement in movement ranging from 20–80% (mean, 46%) after botulinum toxin. In all patients with pain as a result of dystonia, there was substantial improvement. None of the patients worsened and no adverse effects occurred. Botulinum toxin injections offer a potent new treatment for truncal dystonia.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Illinois</li></region></list><tree><country name="États-Unis"><region name="Illinois"><name sortKey="Comella, Cynthia L" sort="Comella, Cynthia L" uniqKey="Comella C" first="Cynthia L." last="Comella">Cynthia L. Comella</name></region><name sortKey="Jaglin, Jeana" sort="Jaglin, Jeana" uniqKey="Jaglin J" first="Jeana" last="Jaglin">Jeana Jaglin</name><name sortKey="Shannon, Kathleen M" sort="Shannon, Kathleen M" uniqKey="Shannon K" first="Kathleen M." last="Shannon">Kathleen M. Shannon</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005009 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005009 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:FBFAB686DC5D67A5E411812E7FA90B90E7BEEB3E
|texte= Extensor truncal dystonia: Successful treatment with botulinum toxin injections
}}
| This area was generated with Dilib version V0.6.23. |  |